ProdIgY Biotech
Developer of avian-derived (IgY) antibody therapeutics focused on microbiome modulation of the gut–liver axis to treat liver diseases. The company develops oral, non-systemic, polyclonal antibody agents that selectively neutralize pathogenic gut microbes and microbial toxins (notably cytolysin-producing Enterococcus faecalis) with the goal of treating alcohol-associated hepatitis and other liver disorders. Pipeline programs include preclinical-to-clinical development candidates for alcohol-associated hepatitis, primary sclerosing cholangitis, and metabolic dysfunction-associated steatohepatitis.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft- versus-host disease
US-12435125-B2
View DetailsHyperimmunized egg product for treatment or prevention of coronavirus infection
US-12324441-B2
View DetailsHyperimmunized egg product for treatment or prevention of coronavirus infection
US-11701423-B2
View Details
Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft- versus-host disease
US-12435125-B2
View DetailsHyperimmunized egg product for treatment or prevention of coronavirus infection
US-12324441-B2
View DetailsHyperimmunized egg product for treatment or prevention of coronavirus infection
US-11701423-B2
View DetailsProducts
PRO-AH-001
Oral IgY-based therapy targeting cytolysin-producing Enterococcus faecalis and its toxin to reduce liver inflammation in alcohol-associated hepatitis.
PRO-AH-002
Pipeline candidate for alcohol-associated hepatitis (stage indicated in company pipeline).
PRO-PSC-001
Pipeline candidate targeting primary sclerosing cholangitis.
PRO-MSH-001
Pipeline candidate for metabolic dysfunction-associated steatohepatitis (MASH).
PRO-AH-001
Oral IgY-based therapy targeting cytolysin-producing Enterococcus faecalis and its toxin to reduce liver inflammation in alcohol-associated hepatitis.
PRO-AH-002
Pipeline candidate for alcohol-associated hepatitis (stage indicated in company pipeline).
PRO-PSC-001
Pipeline candidate targeting primary sclerosing cholangitis.
PRO-MSH-001
Pipeline candidate for metabolic dysfunction-associated steatohepatitis (MASH).
Expertise Areas
- IgY-based antibody therapeutics
- Microbiome-targeted therapies
- Preclinical development and translational research
- Microbiota-humanized animal models
Key Technologies
- Avian-derived IgY antibodies
- Polyclonal antibody production
- Microbiome profiling
- Oral, gut-localized biologic delivery
News & Updates
Preclinical study demonstrating that oral IgY targeting cytolysin and Enterococcus faecalis reduced ethanol-induced liver disease in microbiota-humanized mouse models; selected for the cover of the July 2023 issue of Hepatology.
Preclinical work on IgY antibodies targeting cytolysin was published and selected for the cover of Hepatology (July 2023).
Preclinical study demonstrating that oral IgY targeting cytolysin and Enterococcus faecalis reduced ethanol-induced liver disease in microbiota-humanized mouse models; selected for the cover of the July 2023 issue of Hepatology.
Preclinical work on IgY antibodies targeting cytolysin was published and selected for the cover of Hepatology (July 2023).